In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
MDR/IVDR Implementation – Amendment Transitional Provisions

MDR/IVDR Implementation – Amendment Transitional Provisions

by In2Pharma | Mar 29, 2023 | News

Europe Due to lack of Notified Body (NB) capacity, lack of access to NB for SMEs, supply chain disruptions (Covid-19, Ukraine war,…),…the MDR implementation is creating bottlenecks in product certification. A new regulation ((EU) 2023/607) has been published, amending...

Recent Posts

  • Maximum hospitality limits increased
  • CGR publishes new maximum hourly rates for 2027
  • GAIA self-assessment on hospitality rules now also applies to medical device companies
  • Indexing Issue in Embase: Geneesmiddelenbulletin
  • Update guideline aRMM FAMHP

Follow Us

  • Facebook
  • LinkedIn
An IQVIA Business

IQVIA Logo
IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries and is dedicated to delivering actionable insights and accelerating innovations.

www.iqvia.com

Contact Us

Privacy Policy | Your Privacy Choices | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com |Terloonststraat 22, 1910 Kampenhout, België